Table 1.

Tumor growth characteristics

TDT
TTR 1,000 mm3
Days 1-56
Vehicle8.9 ± 1.217.5 ± 3.0
Irinotecan19.8 ± 2.524.0 ± 3.1
12.5-Vandetanib-Seq12.7 ± 1.621.3 ± 4.0
12.5-Combo-Seq25.8 ± 5.538.8 ± 8.6
12.5-Vandetanib-Conc19.8 ± 3.235.4 ± 7.5
12.5-Combo-Conc30.1 ± 9.1*42.5 ± 5.1*
25-Vandetanib-Seq20.6 ± 2.529.0 ± 4.6
25-Combo-Seq20.3 ± 4.4*25.8 ± 5.7
25-Vandetanib-Con28.8 ± 5.1*39.8 ± 6.3*
25-Combo-Conc38.5 ± 3.3*51.9 ± 1.8*
  • NOTE: Values are expressed as mean ± SE for each group over the given time frame.

    Abbreviations: TDT, tumor doubling time; TTR 1,000 mm3, time to reach 1,000 mm3; Seq, sequential schedule; Conc, concurrent schedule.

  • * Significantly different (P < 0.05) from the vehicle-treated controls by ANOVA analysis with Tukey's multiple comparison test between groups.